These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33885751)

  • 1. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
    Masarova L; DiNardo CD; Bose P; Pemmaraju N; Daver NG; Kadia TM; Chifotides HT; Zhou L; Borthakur G; Estrov Z; Konopleva M; Verstovsek S
    Blood Adv; 2021 Apr; 5(8):2156-2164. PubMed ID: 33885751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
    Chua CC; Roberts AW; Reynolds J; Fong CY; Ting SB; Salmon JM; MacRaild S; Ivey A; Tiong IS; Fleming S; Brown FC; Loo S; Majewski IJ; Bohlander SK; Wei AH
    J Clin Oncol; 2020 Oct; 38(30):3506-3517. PubMed ID: 32687450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
    Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
    Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
    Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
    J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
    Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
    Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.
    Shimony S; Stone RM; Stahl M
    Curr Opin Hematol; 2022 Mar; 29(2):63-73. PubMed ID: 34966123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax in acute myeloid leukemia - current and future directions.
    Lachowiez C; DiNardo CD; Konopleva M
    Leuk Lymphoma; 2020 Jun; 61(6):1313-1322. PubMed ID: 32031033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Kadia TM; Reville PK; Wang X; Rausch CR; Borthakur G; Pemmaraju N; Daver NG; DiNardo CD; Sasaki K; Issa GC; Ohanian M; Montalban-Bravo G; Short NJ; Jain N; Ferrajoli A; Bhalla KN; Jabbour E; Takahashi K; Malla R; Quagliato K; Kanagal-Shamanna R; Popat UR; Andreeff M; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM
    J Clin Oncol; 2022 Nov; 40(33):3848-3857. PubMed ID: 35704787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
    Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
    Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
    Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America.
    Gómez-De León A; Demichelis-Gómez R; Pinedo-Rodríguez A; Enriquez-Vera D; Flores-Jiménez JA; Ceballos-López AA; Rodríguez-Mejorada M; Herrera Riojas MA; Ovilla-Martínez R; Báez-Islas P; Cota-Rangel X; Neme-Yunes Y; Inclán-Alarcón S; López-Flores NJ; Colunga-Pedraza PR; Rodríguez-Zúñiga AC; Gómez-Almaguer D
    Hematology; 2022 Dec; 27(1):249-257. PubMed ID: 35192778
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
    Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I
    Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918
    [No Abstract]   [Full Text] [Related]  

  • 20. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
    Maiti A; Konopleva MY
    Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.